Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Depreciation & Amortization (CF) (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Depreciation & Amortization (CF) for 2 consecutive years, with $181000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 14.56% to $181000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $704000.0 through Dec 2025, up 6.67% year-over-year, with the annual reading at $704000.0 for FY2025, 6.67% up from the prior year.
  • Depreciation & Amortization (CF) hit $181000.0 in Q4 2025 for Connect Biopharma Holdings, up from $179000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $181000.0 in Q4 2025 to a low of $158000.0 in Q4 2024.